Private Portfolio Companies

Algorithm Sciences is a development stage biopharmaceutical company focused on optimizing treatment for pulmonary arterial hypertension (PAH) and developing prostacyclin therapy. Despite many drugs that have been approved for the treatment of PAH, it is recognized in the medical community that therapeutic treatment could be significantly improved. Algorithm’s lead product candidate for PAH treatment is PulmoProst™. Through PulmoProst, the company believes they have the tools and technologies to deliver prostacyclin therapy to achieve improved outcomes in PAH. The company has completed the Special Protocol Assessment (SPA) process with the Center of Drug Evaluation and Research (CDER).

Aperisys, Inc., founded in 2019, focuses on developing immune-oncology assets to benefit patients suffering from a range of cancers.  Through partnerships with Massachusetts General Hospital, Aperisys is able to in-license and progress assets that were pioneered by the Vaccine and Immunotherapy Center at MGH. Aperisys is committed to solving unmet needs in the treatment armamentarium for HPV related cancers, non-small-cell lung cancer and other malignancies.

PD Theranostics (PDTx) leverages proprietary workflows and methods utilizing imaging-based methodologies to diagnose and guide clinical decision making around specific targeted therapies and their efficacy in human disease states, includes cancer, infectious diseases and complications of diabetes including diabetic foot ulcers. This has led to the development of an artificial intelligence driven theranostic that will guide both diagnostic and therapeutic decision making – involving the use of both unique tissue preparation kits and novel algorithms. This approach could be applied to any disease in which diagnosis rests on the histopathological analysis of tissue biopsiesPDTx’s platform can determine the severity of the disease, aid in the refining the pathological diagnosis and allow for optimal treatment decisions. This will potentially help improve patient outcomes and reduce costs to the healthcare system. 

Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital’s novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related). Halovax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapeutics Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized cellular immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.